Janowiec M, Andrzejczyk Z, Marczewska J
Pneumonol Pol. 1989 May;57(5):300-7.
The authors present results of in-vivo and in-vitro studies of combined effect of gentamycin , amikacin and rifampicin , ethambutol, isoniazide on selected standard strains of Mycobacterium sp. (Myc. H37Rv, Myc. An5, Myc. wells, Myc. kirchberg, Myc. kansasii, Myc. intracellulare, and Myc. fortuitum). In in-vitro studies the synergistic effect of gentamycin and amikacin with the tuberculostatic drugs was demonstrable on all Mycobacterium strains. The weakest effect was seen on Myc. fortuitum colonies. In-vivo studies have also shown this synergistic effect on all studied strains, and a much weaker effect when used in monotherapy. The authors have shown the possibility of using combination of gentamycin and amikacin with RMP, EMB, INH in treating Myc. intracellulare infections.
作者展示了庆大霉素、阿米卡星与利福平、乙胺丁醇、异烟肼联合作用于分枝杆菌属选定标准菌株(结核分枝杆菌H37Rv、安5分枝杆菌、韦尔斯分枝杆菌、基尔希贝格分枝杆菌、堪萨斯分枝杆菌、胞内分枝杆菌和偶然分枝杆菌)的体内和体外研究结果。在体外研究中,庆大霉素和阿米卡星与抗结核药物的协同作用在所有分枝杆菌菌株上均得到证实。在偶然分枝杆菌菌落上观察到的效果最弱。体内研究也表明了这种协同作用在所有研究菌株上均存在,且单药治疗时效果要弱得多。作者表明了庆大霉素和阿米卡星与利福平、乙胺丁醇、异烟肼联合使用治疗胞内分枝杆菌感染的可能性。